Medical Science Monitor
February 18, 2026
Łukasz Grabarczyk, Sophia Rebekka Wolfermann, Hubert Oniszczuk et al.
Conventional antidepressant drugs are effective in only approximately 50% of patients with treatment-resistant depression (TRD). Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, offers a promising alternative with an exceptionally rapid antidepressant effect. Although its efficacy in the general TRD population is well established, its use in specific patient subpopulations...
Medical Science Monitor
June 30, 2025
Andrzej Silczuk, Robert Madejek, Tytus Koweszko et al.
4 citations
Psychedelics, derived from the Greek words "psyche" (soul) and "deloun" (revealing), are substances historically and currently considered "soul-revealing". Also termed hallucinogens due to their impact on sensory perception, they are further categorized into hallucinogens, such as lysergic acid diethylamide (LSD), psilocybin, and mescaline; entactogens or empathogens, such as...
Medical Science Monitor
April 23, 2024
Anney Roy, Varsha Subramanian Girija, E. Kitzlerová
Maladaptive daydreaming has been recently identified as a mental disorder and significantly relates to high levels of attentional absorption. As a form of spontaneous and self-generated mental process, daydreaming can lead to the disintegration of attention from the immediate external environment. In extreme cases, patients may develop maladaptive daydreaming comorbid with dissociation,...
Medical Science Monitor
April 27, 2020
Jie Wang, Yajun Wang, Xudong Xu et al.
80 citations
Background This study investigated the effects of various doses of S-ketamine on depression and pain management of cervical carcinoma patients with mild/moderate depression. Material/Methods This randomized, double-blind, controlled study included 417 cervical carcinoma patients who received laparoscopic modified radical hysterectomy from April 2015 to July 2018 and who also had mild/moderate...